文献速递骨质疏松与代谢性骨病创伤骨科

地舒单抗治疗超过10年后腰椎和髋部BMD持续增加

Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years.
PubMed 文献 · Osteoporos Int · 2026-10-23

本文报告一例80岁女性骨质疏松患者,在接受地舒单抗治疗10年后发生左髋骨折,继续治疗3年后腰椎和全髋骨密度分别提高8.0%和6.6%,提示超过10年的地舒单抗治疗可能与骨密度进一步显著增加相关。

要点

  • 地舒单抗治疗超过10年仍可能使腰椎和全髋骨密度进一步增加。
  • 本例中治疗第10年腰椎T值为-2.7,全髋T值为-3.0。
  • 继续治疗3年后腰椎T值升至-2.1,全髋T值升至-2.7。

核心结论

  • 地舒单抗治疗超过10年可能与后续3年腰椎和全髋骨密度显著进一步增加相关。

研究设计与样本

  • 个案报道,描述一例80岁女性骨质疏松患者接受地舒单抗治疗超过10年的骨密度变化。

主要发现

  • 治疗第10年腰椎T值为-2.7(0.754 g/cm2),全髋T值为-3.0(0.572 g/cm2)。
  • 继续治疗3年后腰椎骨密度提高8.0%(0.814 g/cm2,T值-2.1)。
  • 继续治疗3年后全髋骨密度提高6.6%(0.610 g/cm2,T值-2.7)。

关键数值与推荐

  • 患者基线腰椎T值为-4.2(0.585 g/cm2),全髋T值为-4.0(0.503 g/cm2)。
  • 初始使用阿仑膦酸钠70 mg每周一次,后因T值低换用地舒单抗。

临床怎么用

  • 对于长期接受地舒单抗治疗的患者,持续监测骨密度可能有助于评估治疗反应。
  • 本例中骨科老年医学服务建议继续地舒单抗治疗并在3年后重新评估。
  • 部分患者可能需要终身治疗,但需未来研究确认安全性和疗效。

局限性

  • 本文为单个病例报告,证据级别有限。
  • 地舒单抗超过10年的疗效和安全性数据有限,需未来研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Denosumab therapy results in a sustained increase in BMD at the lumbar spine and hip and lower fracture rates during 10 years of treatment. However, data on efficacy and safety beyond 10 years are limited. We present the case of a female who demonstrated a large and continued rise in BMD after 10 years of denosumab therapy. CASE: An 80-year-old woman was referred to our Bone Health Clinic for advice regarding osteoporosis diagnosed 1 year earlier on routine DXA: lumbar spine T-score of -4.2 (0.585 g/cm2) and total hip T-score of -4.0 (0.503 g/cm2). Her GP had commenced her on alendronate 70 mg once weekly. Given her low T-scores, treatment was switched to denosumab, which was continued over the next decade. In her 10th year of treatment, she fell and sustained a left hip fracture. Repeat DXA revealed a T-score of -2.7 (0.754g/cm2) in the lumbar spine and -3.0 (0.572g/cm2) in the total hip. Our orthogeriatric service advised her to continue denosumab until reassessment in 3 years. Follow-up DXA 3 years later revealed an 8.0% improvement in BMD at lumbar spine (0.814 g/cm2, T-score -2.1), 6.6% at the total hip (0.610 g/cm2, T-score -2.7) (see Table 1). Denosumab was continued with advice that lifelong therapy may be needed. DISCUSSION: This case illustrates that denosumab therapy beyond 10 years can be associated with significant further increases over a subsequent 3 years in BMD at both the lumbar spine and total hip. This may allow some patients to achieve a desirable treatment target, though future studies on safety and efficacy are needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Brennan F, Fitzpatrick D, Lannon R, et al. Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years. Osteoporos Int. 2026. PMID: 42909485. doi:10.1007/s00198-026-08281-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。